EverCommerce's expected 107% annual growth rate to reach breakeven is seen as overly optimistic. The company's high debt level adds risk to investing in this loss-making firm.
EverCommerce's debt usage is worrisome due to its EBIT loss and liabilities surpassing its cash and near-term receivables. The company's balance sheet is deemed unfit, making the stock risky. However, future profitability will determine if it can bolster its balance sheet.
EverCommerce is believed to be undervalued given its intrinsic value and bullish future expectations. Investors are advised to consider both the company's strong future outlook and other factors like financial health before making investment decisions.
EverCommerce股票討論
• $MorphoSys(MOR.US)$ 增加 7.9%(簽訂費爾扎塔瑪布和 MOR210 的股權參與和許可協議)
• $Day One Biopharmaceuticals(DAWN.US)$ 增加 7.4%(以每股 15.00 元發售價格為 10 萬股普通股)
• $赫茲租車(HTZ.US)$ 增加 6.1%(授權新的 2.0 億美元股份回購計劃)
• $EverCommerce(EVCM.US)$ +3.6%(宣布 500 萬元購回股計劃)
• $Sprinklr(CXM.US)$ +3.6%(在...
暫無評論